Charles Darwin University

CDU eSpace
Institutional Repository

CDU Staff and Student only

Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia

Getachew, Sisay, Ley-Thriemer, Kamala, Auburn, Sarah, Abera, Adugna, Gadisa, Endalamaw, Aseffa, Abraham, Price, Ric N. and Petros, Beyene (2015). Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malaria Journal,14(Article No. 525).

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 6
Google Scholar Search Google Scholar
Attached Files (Some files may be inaccessible until you login with your CDU eSpace credentials)
Name Description MIMEType Size Downloads
Download this reading LeyThriemer_59120.pdf Published version application/pdf 1.18MB 237
Reading the attached file works best in Firefox, Chrome and IE 9 or later.

IRMA ID 10444xPUB36
Title Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia
Author Getachew, Sisay
Ley-Thriemer, Kamala
Auburn, Sarah
Abera, Adugna
Gadisa, Endalamaw
Aseffa, Abraham
Price, Ric N.
Petros, Beyene
Journal Name Malaria Journal
Publication Date 2015
Volume Number 14
Issue Number Article No. 525
ISSN 1475-2875   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-84951844229
Total Pages 8
Place of Publication United Kingdom
Publisher BioMed Central Ltd.
HERDC Category C1 - Journal Article (DIISR)
Abstract Background
Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ resistance is critical to ensure optimal treatment guidelines. This study aimed to provide data on the therapeutic efficacy of CQ against Plasmodium vivax malaria in southern Ethiopia.

Patients with P. vivax mono-infection aged between 8 months and 65 years were enrolled in a clinical efficacy trial. The study was conducted at four sites in southern Ethiopia. Study participants were treated with a supervised course of CQ (25 mg/kg over three consecutive days), followed by weekly blood film examination and clinical assessment for 28 days. CQ blood concentrations were not assessed. The primary endpoint was the risk of failure at 28 days by survival analysis.


Between May 2010 and December 2013, 288 patients were enrolled in the study (n = 89 in Shele, n = 52 in Guba, n = 57 in Batu and n = 90 in Shone). Baseline characteristics varied significantly between sites. In total 34 (11.8 %) patients were censored during follow up (five with Plasmodium falciparum parasitaemia and 29 lost to follow up). Two (0.7 %) patients experienced early treatment failure and 23 (8 %) late treatment failure. The overall risk of recurrence by day 28 was 9.4 % (95 % CI 6.4–13.6 %) with site-specific estimates of 3.8 % (95 % CI 1.2–11.3) for Shele, 21.9 % (95 % CI 12.2–36.1) for Guba, 5.9 % (95 % CI 1.9–17.3) for Batu and 9.2 % (95 % CI 4.5–17.6) for Shone.

There is evidence of reduced CQ efficacy across three of the four study sites, with the degree of resistance severe enough in Guba to suggest that review of treatment policy may be warranted.
Keywords Malaria
DOI   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
Additional Notes This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Description for Link Link to CC Attribution 4.0 License

© copyright

Every reasonable effort has been made to ensure that permission has been obtained for items included in CDU eSpace. If you believe that your rights have been infringed by this repository, please contact

Version Filter Type
Access Statistics: 194 Abstract Views, 237 File Downloads  -  Detailed Statistics
Created: Tue, 26 Jul 2016, 12:46:51 CST